PTH Specific Neutra™ Antibody Products

Are you struggling with prolonged drug development timelines or inconsistent results in parathyroid hormone (PTH)-related studies? Creative Biolabs' PTH-specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver high-affinity, rigorously validated antibodies. Accelerate your therapeutic discovery and achieve precise modulation of PTH activity with tools designed for reproducibility.

Introduction to PTH

Parathyroid hormone (PTH), a critical regulator of calcium and phosphate homeostasis, is secreted by the parathyroid glands. This 84-amino-acid peptide hormone directly influences bone remodeling, renal calcium reabsorption, and vitamin D metabolism. Dysregulated PTH secretion underpins disorders such as hyperparathyroidism and hypoparathyroidism, making it a pivotal therapeutic target in metabolic and renal diseases.

• Structural Insights

The N-terminal region (residues 1–34) of PTH is essential for receptor binding and activation, while the C-terminal region modulates stability and clearance. Its helical structure interacts with the PTH1 receptor (PTHR1), a class B G protein-coupled receptor (GPCR). Conformational flexibility enables binding to multiple receptor states, driving both anabolic and catabolic skeletal effects.

• Related Signaling Pathways

PTH signaling primarily engages the PTHR1, which activates cAMP/PKA and PLC/PKC pathways. Sustained receptor activation promotes bone resorption via RANKL induction in osteoblasts, while intermittent PTH exposure stimulates osteoblast differentiation. Crosstalk with Wnt/β-catenin and FGF23 pathways further integrates PTH into systemic mineral regulation.

Fig.1 Signaling pathways induced by the PTH and PTHR1 binding.¹

• Associated Pathologies

Hyperparathyroidism—characterized by excessive PTH secretion—leads to hypercalcemia, osteoporosis, and vascular calcification. Conversely, hypoparathyroidism results in hypocalcemia and neuromuscular dysfunction. Secondary hyperparathyroidism commonly accompanies chronic kidney disease (CKD), highlighting PTH's role in renal osteodystrophy.

Applications of Anti-PTH Antibodies

• Precision Diagnostics for Hyperparathyroidism

Anti-PTH antibodies facilitate rapid quantification of intact PTH in serum, distinguishing primary from secondary hyperparathyroidism. This is critical for guiding surgical intervention or calcimimetic therapy in CKD patients.

• Therapeutic Candidate Evaluation

Neutralizing antibodies serve as benchmarks for assessing novel PTH analogs or receptor antagonists. By mimicking endogenous PTH blockade, they validate drug efficacy in preclinical osteoporosis or hypercalcemia models.

• Mechanistic Studies in Bone Biology

In vitro and in vivo models using anti-PTH antibodies clarify the hormone's dual role in bone formation and resorption. Researchers leverage these tools to explore PTH's crosstalk with osteocyte-derived sclerostin or vitamin D pathways.

• CKD-Related Mineral Disorder Management

Neutralizing antibodies aid in developing therapies for renal osteodystrophy by targeting excessive PTH signaling. They also help identify biomarkers to monitor treatment responses to phosphate binders or vitamin D analogs.

Anti-PTH Neutralizing Antibodies

Creative Biolabs offers PTH-specific Neutra™ antibody products, empowering researchers to overcome challenges in metabolic disease research and drug development. With rigorously validated specificity and functional reliability, our antibodies are indispensable for advancing diagnostics and therapeutics research. The PTH-Specific Antibodies are engineered to target epitopes critical for PTHR1 engagement. Our antibodies exhibit:

- High specificity: Minimal cross-reactivity with PTH-related peptide (PTHrP) or fragmented PTH.

- Functional neutralization: Block PTH-induced cAMP production and osteoclast activation.

- Versatility: Validated for ELISA, immunoprecipitation, and in vivo efficacy studies.

These tools enable researchers to dissect PTH signaling, screen drug candidates, and develop diagnostic assays for calcium-related disorders. Contact our team today to discuss your project requirements.

REFERENCE

1. Lombardi, Giovanni, et al. "Physical activity-dependent regulation of parathyroid hormone and calcium-phosphorous metabolism." International journal of molecular sciences 21.15 (2020): 5388. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms21155388